前列腺特异性抗原上表位的荟萃分析确定了机会和知识差距。
A meta-analysis of epitopes in prostate-specific antigens identifies opportunities and knowledge gaps.
发表日期:2023 Sep 05
作者:
Gabriele Foos, Nina Blazeska, Morten Nielsen, Hannah Carter, Zeynep Kosaloglu-Yalcin, Bjoern Peters, Alessandro Sette
来源:
CYTOKINE & GROWTH FACTOR REVIEWS
摘要:
癌症抗原数据库和分析资源(CEDAR)是一个新开发的癌症抗原数据的存储库,这些数据来自同行评议的出版物,其中包括特异性表位的T细胞、抗体和MHC配体测定。本文将重点介绍CEDAR的功能,并阐明与表位相关的前列腺癌研究的进展。元分析集中在描述8个前列腺特异性(PS)抗原表位的子集数据。这些蛋白质与460个表位相关联,其中包括187个T细胞表位、109个B细胞表位和271个MHC配体表位。表位的数量与蛋白质的长度无关,但我们发现特定PS抗原的引用次数与报告的表位数之间存在显著正相关性。共发现44个不同的I类和27个II类限制因子,其中以HLA-A*02:01和HLA-DRB1*01:01描述的表位最多。细胞因子测定主要限于IFNg测定,仅进行了很少数量的四聚体测定。单克隆和多克隆B细胞反应是平衡的,ELISA/免疫印迹测定中研究的表位最多。此外,表位通常以与前列腺癌相关的方式进行描述,很少具体说明疾病状态。我们发现,在体和肿瘤识别测定很少,具有注释的B/T细胞受体信息的表位数量有限。通过使用ImmunomeBrowser工具,我们确定了潜在的免疫优势区域。CEDAR为与前列腺特异性抗原相关的表位提供了一个综合的存储库。这个具有丰富可搜索的T细胞、B细胞和MHC配体信息的表位数据库为科学界提供了一个有用的工具。同时,我们还发现了一些可以通过实验分析解决的重要知识空白。版权©2023。由Elsevier Inc.出版。
The Cancer Epitope Database and Analysis Resource (CEDAR) is a newly developed repository of cancer epitope data from peer-reviewed publications, which includes epitope-specific T cell, antibody, and MHC ligand assays. Here we focus on prostate cancer as our first cancer category to demonstrate the capabilities of CEDAR, and to shed light on the advances of epitope-related prostate cancer research.The meta-analysis focused on a subset of data describing epitopes from 8 prostate-specific (PS) antigens. A total of 460 epitopes were associated with these proteins, 187 T cell, 109B cell, and 271 MHC ligand epitopes. The number of epitopes was not correlated with the length of the protein; however, we found a significant positive correlation between the number of references per specific PS antigen and the number of reported epitopes. Forty-four different class I and 27 class II restrictions were found, with the most epitopes described for HLA-A*02:01 and HLA-DRB1*01:01. Cytokine assays were mostly limited to IFNg assays and a very limited number of tetramer assays were performed. Monoclonal and polyclonal B cell responses were balanced, with the highest number of epitopes studied in ELISA/Western blot assays. Additionally, epitopes were generically described as associated with prostate cancer, with little granularity specifying diseases state. We found that in vivo and tumor recognition assays were sparse, and the number of epitopes with annotated B/T cell receptor information were limited. Potential immunodominant regions were identified by the use of the ImmunomeBrowser tool.CEDAR provides a comprehensive repository of epitopes related to prostate-specific antigens. This inventory of epitope data with its wealth of searchable T cell, B cell and MHC ligand information provides a useful tool for the scientific community. At the same time, we identify significant knowledge gaps that could be addressed by experimental analysis.Copyright © 2023. Published by Elsevier Inc.